PPT-HIV-HCV Coinfection in the era of effective antiviral therapy

Mark Sulkowski MD Professor of Medicine Medical Director Viral Hepatitis Center Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading specific causes of death amongst HIVpositive individuals in the DAD study. G. . Ntetskas. , V. . Papastergiou. , L. . Skorda. , A. . Katsili. , E. . Anastasiou. , M. . Stampori. , E. . Asonitis. , F. . Labrianou. , I. . Familias. , I. . Karagiorgi. , M. . Kladas. , S. . Karatapanis. Todd S. Wills, MD. SPNS HCV Treatment Expansion Initiative. Evaluation and Technical Assistance Center. Infectious Disease Specialist. HCV Response Rates in HIV+ and HIV- Patients Treated With . PegIFN. . Piri. MD . September 16. th. 2016. Grand Rounds. CMV Retinitis . CC. Shadow in upper part of visual field with the left eye . HPI. 40 . yo. Caucasian female presents with blurred vision in . superonasal. Dalya. Basil. Antiviral Chemotherapy . (Prevention and Treatment of Viral Infection). Viruses are a leading cause of disease and death worldwide. Although public health measures and vaccines are the most effective ways to control many viral infections, preventive measures have not succeeded for numerous viral diseases. For some of these diseases, antiviral drugs have been developed.. Overview. Brief History. Psychological Treatments. Biomedical Treatments. Client-Therapist Relationship. Is Treatment Effective?. History. Earliest history. Mental illness believed to be caused by evil spirits. Presented by: . Fabian Cretu, Beverly-Ann Oliver, Kristina Miclat, Maeryl Sumagang. PHM142. September 25, 2018. PHM142 Fall . 2018. Instructor: . Ms. Maya Latif. Coordinator: Dr. J. Henderson. HIV. . Case. 47-Year-Old . Man With Asymptomatic HIV Infection. Case (cont). Initial Clinical Presentation. Laboratory Results. HepaScore. ®. A Composite Biomarker Panel for Liver Fibrosis. Hepatic Steatosis in Patients With HIV/HCV Coinfection. Amber Wheeler, MD. WIHS Scientific Meeting. June 30, 2014. Objectives. To discuss:. Background . Aims. Preliminary “rough” data. Future Directions. HIV-infected . persons have increased. odds of . Resistance to HCV DAAs: What is the threat level?. HCV Biology is the basis for resistance. HCV biology is the basis for cure. Frequency of Protease Resistance Mutations Prior to Therapy. Emergence of Pre-existing Resistant Variants During Treatment with DAA. JAKARTA (CAPITAL CITY OF INDONESIA). DENGUE CASES IN INDONESIA. DENGUE CASES IN INDONESIA. Antiviral to dengue VIRUS (DENV). Antiviral to dengue VIRUS (DENV). ANIMAL MODEL. TITER OF DENV FROM MICE SERA. Treating Information for People at High Risk for Serious Flu ComplicationsDo you have Asthma Chronic Obstructive Pulmonary Disease Diabetes or Heart Disease If so you are at high risk of serious illn Dr.. . Nirbhay. Kumar. Asstt. . Professor & Head. Deptt. . of Veterinary Pharmacology & Toxicology. Bihar Veterinary College, Bihar Animal Sciences University, Patna. Viral Chemotherapy. Difficult. Singh B, Huang H, Morton DP, Johnson GP, Gutfraind A, Galvani AP, et al. Optimizing Distribution of Pandemic Influenza Antiviral Drugs. Emerg Infect Dis. 2015;21(2):251-258. https://doi.org/10.3201/eid2102.141024. Background. Seasonal influenza is estimated to cause approximately 300,000 to 650,000 deaths worldwide annually. Currently, recommended antiviral agents for influenza (. oseltamivir. ) have not been studied in placebo controlled randomised trials to demonstrate survival benefit in hospitalized patients with influenza.